Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Restructuring Costs (2018 - 2021)

Ironwood Pharmaceuticals (IRWD) has disclosed Restructuring Costs for 4 consecutive years, with -$73000.0 as the latest value for Q3 2021.

  • Quarterly Restructuring Costs fell 105.93% to -$73000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $14.1 million through Sep 2021, up 1291.12% year-over-year, with the annual reading at $15.4 million for FY2020, 327.28% up from the prior year.
  • Restructuring Costs hit -$73000.0 in Q3 2021 for Ironwood Pharmaceuticals, up from -$282000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $14.2 million in Q4 2020 to a low of -$282000.0 in Q2 2021.
  • Historically, Restructuring Costs has averaged $2.6 million across 4 years, with a median of $700000.0 in 2018.
  • Biggest five-year swings in Restructuring Costs: crashed 107.43% in 2019 and later skyrocketed 27311.54% in 2020.
  • Year by year, Restructuring Costs stood at $700000.0 in 2018, then plummeted by 107.43% to -$52000.0 in 2019, then surged by 27311.54% to $14.2 million in 2020, then plummeted by 100.52% to -$73000.0 in 2021.
  • Business Quant data shows Restructuring Costs for IRWD at -$73000.0 in Q3 2021, -$282000.0 in Q2 2021, and $311000.0 in Q1 2021.